Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Language
  • +91 11 4925 6000
  • Request information
  • +91 11 4925 6000
  • Part of brands: |
IndiaIndia
  • Part of brands: |
  • We guide you
    • Fertility
    • Inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS+ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • ALICE
      • Endometrio
      • Family POC
    • Patients
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS + ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • Family POC
      • ALICE
      • Endometrio
  • Diagnostic
  • About us
    • Igenomix Research
    • About Igenomix
  • ACADEMY
Genomics Precision Diagnostic > Rare Disease Precision Panel > DiGeorge Syndrome  Precision Panel

DiGeorge Syndrome Precision Panel

DiGeorge Syndrome (DGS) is one of a group of phenotypically similar disorders including velocardiofacial syndrome (VCFS) and conotruncal anomaly face (CTAF).
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • DiGeorge Syndrome (DGS) is one of a group of phenotypically similar disorders including velocardiofacial syndrome (VCFS) and conotruncal anomaly face (CTAF). These disorders share a microdeletion of chromosome 22q11.2, a region known as the DiGeorge critical region. Since there are overlapping phenotypic features between these syndromes, they have been designated as 22q11.2 deletion syndromes. It is one of the most common chromosomal microdeletion disorders. The 22q11.2 deletion results in a range of embryonic developmental disruptions involving the head, nek, brain, skeleton, and kidneys. There is also a defect in T cell production which in turn increases susceptibility for infections as well autoimmunity. Neuropsychiatric manifestations of these disorders cause moderate/severe impairment of functionality in these patients. The prognosis for these disorders is highly variable, depending on the nature and degree of involvement of different organs. 
  • The Igenomix DiGeorge Syndrome Precision Panel can serve as a directed and accurate diagnostic tool ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes. 

Indication

  • The Igenomix DiGeorge Syndrome Precision Panel is indicated in those cases where there is a clinical suspicion or diagnosis with or without the following manifestations:  
    • Retrognathia or micrognathia 
    • Long face 
    • High and broad nasal bridge 
    • Narrow palpebral fissures 
    • Small teeth  
    • Short philtrum  
    • Low-set, malformed ears 
    • Congenital heart defects 
    • Hypocalcemia 
    • Cognitive, behavioral and psychiatric problems 
    • Increased susceptibility to infections 

Clinical Utility

The clinical utility of this panel is: 

  • The genetic and molecular diagnosis for an accurate clinical diagnosis and improve prognosis. 
  • Early initiation of treatment with a multidisciplinary approach involving pediatrics, general medicine, surgery, psychiatry, psychology, interventional therapies (physical, occupational, speech, language and behavioral).   
  • Start early medical care with calcium supplementation, surgical care and bone marrow transplantation for profound immunodeficiency, early surveillance and prevention of complications. 
  • Risk assessment and genetic counselling of asymptomatic family members to identify the individuals at risk. 
  • Improvement of delineation of genotype-phenotype correlation. 

Genes & Diseases

Methodology

References

See scientific referrals

Butts SC. The facial phenotype of the velo-cardio-facial syndrome. Int J Pediatr Otorhinolaryngol. 2009 Mar. 73(3):343-50 

McDonald-McGinn, D. M., & Sullivan, K. E. (2011). Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine, 90(1), 1–18. https://doi.org/10.1097/MD.0b013e3182060469 

McDonald-McGinn, D. M., Sullivan, K. E., Marino, B., Philip, N., Swillen, A., Vorstman, J. A., Zackai, E. H., Emanuel, B. S., Vermeesch, J. R., Morrow, B. E., Scambler, P. J., & Bassett, A. S. (2015). 22q11.2 deletion syndrome. Nature reviews. Disease primers, 1, 15071. https://doi.org/10.1038/nrdp.2015.71 

Kuo, C. Y., Signer, R., & Saitta, S. C. (2018). Immune and Genetic Features of the Chromosome 22q11.2 Deletion (DiGeorge Syndrome). Current allergy and asthma reports, 18(12), 75. https://doi.org/10.1007/s11882-018-0823-5 

Morrow, B. E., McDonald-McGinn, D. M., Emanuel, B. S., Vermeesch, J. R., & Scambler, P. J. (2018). Molecular genetics of 22q11.2 deletion syndrome. American journal of medical genetics. Part A, 176(10), 2070–2081. https://doi.org/10.1002/ajmg.a.40504 

Fung, W. L., Butcher, N. J., Costain, G., Andrade, D. M., Boot, E., Chow, E. W., Chung, B., Cytrynbaum, C., Faghfoury, H., Fishman, L., García-Miñaúr, S., George, S., Lang, A. E., Repetto, G., Shugar, A., Silversides, C., Swillen, A., van Amelsvoort, T., McDonald-McGinn, D. M., & Bassett, A. S. (2015). Practical guidelines for managing adults with 22q11.2 deletion syndrome. Genetics in medicine : official journal of the American College of Medical Genetics, 17(8), 599–609. https://doi.org/10.1038/gim.2014.175 

descargar

Detail description

Download



IGENOMIX_PartOfVitrolifeGroup_black

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

OUR SERVICES

Genetic solutions
Learn about genetics
How to send a sample

ABOUT US

About Igenomix
Contact
Quality
Work with us

FOLLOW IGENOMIX

Blog: Path to fertility

  +91 11 4925 6000
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Language

[2024] © Igenomix Privacy policy Quality policy Legal note Cookies policy




  • We guide you
    • Fertility
    • Inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS+ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • ALICE
      • Endometrio
      • Family POC
    • Patients
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS + ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • Family POC
      • ALICE
      • Endometrio
  • Diagnostic
  • About us
    • Igenomix Research
    • About Igenomix
  • ACADEMY
  • Language
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT